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BACKGROUND
More than 80% of deaths from cardiovascular disease are estimated to occur in 
low-income and middle-income countries, but the reasons are unknown.
METHODS
We enrolled 156,424 persons from 628 urban and rural communities in 17 coun-
tries (3 high-income, 10 middle-income, and 4 low-income countries) and assessed 
their cardiovascular risk using the INTERHEART Risk Score, a validated score for 
quantifying risk-factor burden without the use of laboratory testing (with higher 
scores indicating greater risk-factor burden). Participants were followed for inci-
dent cardiovascular disease and death for a mean of 4.1 years.
RESULTS
The mean INTERHEART Risk Score was highest in high-income countries, inter-
mediate in middle-income countries, and lowest in low-income countries (P<0.001). 
However, the rates of major cardiovascular events (death from cardiovascular 
causes, myocardial infarction, stroke, or heart failure) were lower in high-income 
countries than in middle- and low-income countries (3.99 events per 1000 person-
years vs. 5.38 and 6.43 events per 1000 person-years, respectively; P<0.001). Case 
fatality rates were also lowest in high-income countries (6.5%, 15.9%, and 17.3% 
in high-, middle-, and low-income countries, respectively; P = 0.01). Urban com-
munities had a higher risk-factor burden than rural communities but lower rates 
of cardiovascular events (4.83 vs. 6.25 events per 1000 person-years, P<0.001) and 
case fatality rates (13.52% vs. 17.25%, P<0.001). The use of preventive medications 
and revascularization procedures was significantly more common in high-income 
countries than in middle- or low-income countries (P<0.001).
CONCLUSIONS
Although the risk-factor burden was lowest in low-income countries, the rates of 
major cardiovascular disease and death were substantially higher in low-income 
countries than in high-income countries. The high burden of risk factors in high-
income countries may have been mitigated by better control of risk factors and 
more frequent use of proven pharmacologic therapies and revascularization. 
(Funded by the Population Health Research Institute and others.)
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Cardiovascular Risk and Events in 17 Countries
Worldwide, 18 million deaths an-nually are attributed to cardiovascular diseases.1 From the 1930s to the 1950s, 
the rate of cardiovascular disease increased in 
high-income countries, but during this period, the 
rates were low in middle- and low-income coun-
tries.2,3 Since the mid-1970s, the rate of death 
from cardiovascular diseases has declined mark-
edly in several high-income countries, owing to 
reductions in risk factors and improved manage-
ment of cardiovascular disease.4 By contrast, the 
incidence of cardiovascular disease has been in-
creasing in some low-income and middle-income 
countries,5,6 with 80% of the global burden esti-
mated to occur in these countries.1 It is not known 
whether the risk-factor burden and the incidence 
of cardiovascular disease are now higher in low- 
and middle-income countries than in high-income 
countries, whether mortality after a cardiovascu-
lar event is higher in low- and middle-income 
countries than in high-income countries, or wheth-
er both are true.
To address these questions, we initiated the 
Prospective Urban Rural Epidemiologic (PURE) 
cohort study involving more than 150,000 adults 
in 17 high-, middle-, and low-income countries. 
We now report the risk-factor burden, the incidence 
of cardiovascular disease, related case fatality 
rates, and mortality over the course of 4.1 years 
of follow-up.
Me thods
Study Design
Details of the design and methods of the PURE 
study have been published previously 7-10 and are 
summarized in the Supplementary Appendix, 
available with the full text of this article at NEJM 
.org. Briefly, we prospectively recruited 156,424 
persons from 628 communities in 17 low-, mid-
dle-, and high-income countries (Table S1 in the 
Supplementary Appendix).7-10 Recruitment began 
in January 2003. We selected the number and 
locations of countries with a view toward bal-
ancing the goal of including a large number of 
communities in countries with a wide range of so-
cioeconomic circumstances with the goal of re-
cruiting participants for whom successful long-
term follow-up would be feasible. It was not 
considered practical to implement strict propor-
tionate sampling of the whole world, any specific 
country, or any specific region.
Using World Bank classifications of the income 
levels of countries at the time the PURE study 
was started, we included 4 low-income countries 
(Bangladesh, India, Pakistan, and Zimbabwe), 
10 middle-income countries (Argentina, Brazil, 
Chile, China, Colombia, Iran, Malaysia, Poland, 
South Africa, and Turkey), and 3 high-income 
countries (Canada, Sweden, and the United Arab 
Emirates). In each country, we selected urban and 
rural communities within participating sites on 
the basis of prespecified guidelines7-10 (Table S2 in 
the Supplementary Appendix).
Households within a community were select-
ed with the goal of achieving a broadly represen-
tative sample of that community (see the Supple-
mentary Appendix for details). A household was 
eligible if at least one member was 35 to 70 years 
of age and the members of the household in-
tended to remain at the current address for at 
least 4 more years. All eligible persons who 
provided written informed consent were enrolled 
(response rate, 78%).
By including persons from both urban and 
rural communities in low-, middle-, and high-
income countries on five continents, we expect-
ed substantial variations in health determinants 
and outcomes. Information concerning the rep-
resentativeness of the PURE cohort is provided 
in Figures S1 through S4 and the Methods sec-
tion in the Supplementary Appendix.
Study Oversight and Management
The study was designed by the first author and 
supervised by the first two authors together with 
each country’s designated national leader (see the 
Supplementary Appendix). The PURE study was 
funded by nonprofit, governmental, and industry 
sponsors. The funders of the study had no role 
in the design or conduct of the study, in the col-
lection, analysis, or interpretation of the data, or 
in the writing of the manuscript. The study was 
approved by the ethics committee at each partici-
pating center and at Hamilton Health Sciences, 
Hamilton, Ontario, Canada. All the participants 
provided written informed consent.
Data Collection
We collected data at national, community, house-
hold, and individual levels using standardized 
questionnaires.7 Questions about age, sex, educa-
tion, smoking status, hypertension, diabetes, and 
obesity were identical to those in the INTERHEART 
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and INTERSTROKE studies.11,12 Participants were 
considered to have hypertension if they had 
blood pressure higher than 140/90 mm Hg or if 
they reported a history of hypertension. Partici-
pants were considered to have diabetes if they 
reported having diabetes or if they had a fasting 
glucose level higher than 7.0 mmol per liter (126 
mg per deciliter). A total cholesterol level higher 
than 5.2 mmol per liter (201 mg per deciliter) 
was considered to be an elevated level.
Follow-up occurred between 2008 and 2013. 
Information on specific events was obtained from 
participants or their family members, and events 
were adjudicated centrally in each country by 
trained physicians who reviewed verbal (i.e., oral) 
autopsy reports13,14 and medical records with the 
use of standardized definitions. Major cardiovas-
cular events included death from cardiovascular 
causes and nonfatal stroke, myocardial infarc-
tion, and heart failure. Nonmajor cardiovascular 
events included all other cardiovascular disease 
events that led to hospitalization. Details regard-
ing the determination and adjudication of risk 
factors and end points are provided in the Sup-
plementary Appendix.
INTERHEART Risk Score
To quantify the risk-factor burden, we calculated 
the INTERHEART Risk Score15 for each partici-
pant, using the version that did not include data 
on cholesterol levels. The INTERHEART Risk Score 
is a validated score that includes data on age; sex; 
status with respect to smoking, diabetes, high 
blood pressure, and family history of heart dis-
ease; waist-to-hip ratio; psychosocial factors; diet; 
and physical activity. Scores range from 0 to 48, 
with higher scores indicating a greater risk-fac-
tor burden. Details concerning the development 
and validation of the INTERHEART Risk Score 
have been published previously15 and are also pro-
vided in the Supplementary Appendix; the scoring 
system itself is shown in Table S3 in the Supple-
mentary Appendix, with validation information 
in Table S4 in the Supplementary Appendix.
Statistical Analysis
Means and confidence intervals were calculated 
according to urban and rural location and the 
economic status of the country. For all cardiovas-
cular events and deaths, the time to an event was 
calculated to obtain incidence rates per 1000 per-
son-years that were age-standardized after adjust-
ment for sex. Case fatality rates were calculated 
for myocardial infarction, stroke, and heart fail-
ure after adjustment for duration of follow-up, 
age, and sex. A Cox proportional-hazards model 
was used to test for trends in the incidence of 
cardiovascular disease across high-income, mid-
dle-income, and low-income countries and be-
tween urban versus rural locations. Given the 
multiplicity of comparisons, P values should be 
interpreted cautiously, except when they are very 
small (e.g., P<0.001).
R esult s
Study Participants
We identified 388,796 persons from 108,927 
households in 628 communities (348 urban and 
280 rural) in 17 countries on five continents. 
Recruitment started in India in 2003; however, 
most persons were recruited between 2005 and 
2009. A total of 200,905 of the potential partici-
pants we identified (51.7%) were eligible for the 
study, and 156,424 of the eligible persons (77.9%) 
participated. Characteristics of eligible and en-
rolled persons were generally similar except for 
a slightly higher proportion of women and of 
persons with hypertension and diabetes in the 
latter group (Table S5 in the Supplementary Ap-
pendix). Table 1 shows the baseline characteris-
tics of the enrolled participants.
Risk-Factor Burden
The mean INTERHEART Risk Score was highest 
in high-income countries (12.89; 95% confidence 
interval [CI], 12.79 to 12.98), intermediate in mid-
dle-income countries (10.47; 95% CI, 10.43 to 
10.50), and lowest in low-income countries (8.28; 
95% CI, 8.23 to 8.34) (P<0.001) (Fig. 1). The 
INTERHEART Risk Score was higher in rural 
areas than in urban areas in high-income coun-
tries (13.43 vs. 12.67, P<0.001) but lower in rural 
areas than in urban areas in middle-income 
countries (10.11 vs. 10.81, P<0.001) and in low-
income countries (7.57 vs. 9.09, P<0.001). Total 
cholesterol levels (Table 1) were highest in high-
income countries, intermediate in middle-income 
countries, and lowest in low-income countries, 
but information on cholesterol levels was avail-
able for only about 75% of the participants.
Medications and Revascularization
Among participants without cardiovascular dis-
ease at baseline, the use of antiplatelet drugs 
was highest in high-income countries, interme-
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diate in middle-income countries and lowest in 
low-income countries (8.1%, 2.8%, and 0.5%, re-
spectively); a similar pattern was seen in the use 
of beta-blockers (4.5%, 3.0%, and 1.8%, respec-
tively), blockers of the renin–angiotensin system 
(10.5%, 4.8%, and 0.8%, respectively), and statins 
(10.3%, 1.6%, and 0.3%, respectively). The patterns 
were similar among persons with prevalent car-
diovascular disease.14 The frequency of coronary 
revascularization (either coronary-artery bypass 
grafting or percutaneous coronary intervention) 
was highest in high-income countries, interme-
diate in middle-income countries, and lowest in 
low-income countries.
Follow-up
The mean duration of follow-up was 4.1 years. 
The rate of complete follow-up was 92.8% (97.5% 
in high-income countries, 94.4% in middle-income 
countries, and 85.9% in low-income countries). 
An additional 4.8% of the participants had partial 
follow-up information, and 2.4% had no follow-
up information available. Follow-up rates were 
similar in urban and rural communities in high-
income countries (97.2% and 98.1%, respectively) 
and middle-income countries (94.2% and 94.5%, 
respectively) but were lower in urban communi-
ties than in rural communities in low-income 
countries (76.8% vs. 94.0%). Characteristics of all 
the study participants, as compared with partici-
pants with follow-up information, are shown in 
Table S6 in the Supplementary Appendix.
Overall Events
There were 3900 deaths among 152,463 partici-
pants with confirmed vital status (2.6%). Of the 
152,606 participants with complete or partial fol-
low-up data, 1736 had a myocardial infarction 
(1.1%), 1317 had a stroke (0.9%), 414 had heart 
failure (0.3%), and 3483 had at least one major 
cardiovascular event (2.3%). An additional 1163 
participants (0.8%) were hospitalized for other 
cardiovascular reasons (termed nonmajor cardio-
vascular events). In total, 4646 participants (3.0%) 
had at least one cardiovascular event.
Cardiovascular Events According to Country 
Income Stratum
There were 216 deaths (2.43 per 1000 person-
years of follow-up) in high-income countries, 2052 
deaths (5.59 per 1000 person-years of follow-up) 
in middle-income countries, and 1632 deaths (9.23 
per 1000 person-years of follow-up) in low-income 
countries (P<0.001 for trend) (Fig. 2, and Table S7 
in the Supplementary Appendix). A similar pattern 
was seen for myocardial infarction (Table S7 in the 
Supplementary Appendix). There was no consis-
tent pattern for stroke or heart failure.
The overall rates of major cardiovascular events 
showed a pattern similar to that for mortality, 
with rates of 3.99, 5.38, and 6.43 events per 1000 
person-years in high-, middle-, and low-income 
countries, respectively (P<0.001) (Fig. 2, and Table 
S7 in the Supplementary Appendix). By contrast, 
nonmajor cardiovascular events (cardiovascular 
events, other than major cardiovascular events, 
that required hospitalization) showed the oppo-
site pattern, with event rates of 3.69, 1.72, and 
1.10 per 1000 person-years in high-, middle-, and 
low-income countries, respectively (P<0.001). The 
most common nonmajor cardiovascular events 
are shown in Table S8 in the Supplementary Ap-
pendix.
Association between INTERHEART Risk Score 
and Cardiovascular Events
The INTERHEART Risk Score predicted cardio-
vascular events (data not shown); however, with-
in each stratum of the INTERHEART Risk Score, 
the rates of major cardiovascular events and of 
Figure 1. Risk-Factor Burden in High-, Middle-, and 
Low-Income Countries, as Measured by the INTER-
HEART Risk Score.
The INTERHEART Risk Score is a validated score for 
quantifying risk‑factor burden without the use of labo‑
ratory testing. Scores range from 0 to 48, with higher 
scores indicating a greater risk‑factor burden. The risk 
score is shown according to the income status of the 
17 countries included in the study and according to 
whether the communities within those countries were 
urban or rural.
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death were lowest in high-income countries, in-
termediate in middle-income countries, and high-
est in low-income countries (data not shown). After 
adjustment for variations in the INTERHEART 
Risk Score among the three income strata, the 
rates of major cardiovascular events were 3.64, 
5.23, and 7.39 per 1000 person-years in high-, 
middle-, and low-income countries, respectively 
(P<0.001), and the rates of death were 2.19, 5.50, 
and 9.84 per 1000 person-years, respectively 
(P<0.001).
Case Fatality Rates According to Country 
Income Stratum
The proportions of participants with major cardio-
vascular disease who died (the case fatality rates) 
were higher in low- and middle-income coun-
tries than in high-income countries (6.50% in 
high-income countries, 15.86% in middle-income 
countries, and 17.28% in low-income countries; 
P = 0.01) (Fig. 3, and Table S9 in the Supplemen-
tary Appendix). This relationship was consistent 
among patients with myocardial infarction, those 
with stroke, and those with heart failure.
Cardiovascular Events and Case Fatality Rates 
According to Urban versus Rural Location
The rate of major cardiovascular events was lower 
in urban communities than in rural communities 
(4.83 events vs. 6.25 events per 1000 person-years, 
P<0.001) (Fig. 4A), as were the rates of fatal car-
diovascular events (1.71 events vs. 3.09 events 
per 1000 person-years, P<0.001) and of deaths 
from any cause (4.48 deaths vs. 8.01 deaths per 
1000 person-years, P<0.001) (Table S10 in the 
Supplementary Appendix). The rate of nonmajor 
cardiovascular events showed the opposite trend 
(2.12 events per 1000 person-years in urban com-
munities vs. 1.50 events per 1000 person-years in 
rural communities, P<0.001). In both high-income 
and low-income countries, case fatality rates were 
similar in rural and urban areas, but in middle-
income countries, the rates were higher in rural 
areas than in urban areas (Fig. 4B, and Table S11 
in the Supplementary Appendix).
Discussion
Our study has three major findings. First, the 
incidence of major cardiovascular events was 
highest in low-income countries, despite the fact 
that these countries had the lowest risk-factor 
burden. In contrast, the incidence of nonmajor 
cardiovascular events was highest in high-income 
countries. Second, case fatality rates after major 
cardiovascular events and the rates of death from 
any cause were highest in low-income countries, 
intermediate in middle-income countries, and low-
est in high-income countries. Third, the rates of 
major cardiovascular events and the rates of death 
from any cause were higher in rural communities 
than in urban communities in middle-income 
countries and low-income countries, whereas the 
risk-factor burden was higher in the urban com-
Figure 2. Cardiovascular Disease Event Rates in High-, Middle-, and Low-Income Countries.
Major cardiovascular events included death from cardiovascular causes, stroke, myocardial infarction, and heart failure. Nonmajor  
cardiovascular events included all other cardiovascular disease events that led to hospitalization.
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munities than in the rural communities in those 
countries.
The version of the INTERHEART Risk Score 
that is calculated without the use of laboratory 
testing was developed with data from the 
INTERHEART study for use in resource-limited 
settings. It has been validated in a cohort se-
lected from 21 countries15 and predicts cardio-
vascular disease and mortality in the PURE study 
(data not shown). However, within each stratum 
of risk score, the rates of major cardiovascular 
events and of death were lowest in high-income 
countries, intermediate in middle-income coun-
tries, and highest in low-income countries, 
whereas for the rates of nonmajor cardiovascular 
events, the reverse trend was seen. These find-
ings indicate that influences other than risk 
factors are important in determining outcomes 
at the country level. Possible contributing factors 
could include access to and affordability of 
health services and medications, thresholds for 
diagnoses and treatments, and educational level 
of the population. This interpretation is support-
ed by parallel observations in the PURE study of 
the greater use of preventive drugs and coronary 
revascularization, better control of hyperten-
sion, and lower current smoking rates (all mark-
ers of better health care systems) in high-income 
countries,9,10 which may mitigate higher risk-
factor levels in those countries.
The similarity in the rates of major cardiovas-
cular disease and deaths among urban and rural 
participants in high-income countries may reflect 
the structure of the health systems in the three 
high-income countries we studied, with univer-
sal coverage ensuring good access in both urban 
and rural areas. By contrast, in most middle- 
and low-income countries, there may be greater 
differences between urban and rural communi-
ties in the educational level of the population as 
well as in the access to and quality and afford-
ability of health care, which may contribute to 
higher rates of death from cardiovascular causes 
in rural areas, despite a lower risk-factor burden. 
These data therefore also suggest that health 
care systems are likely to have a large impact on 
cardiovascular disease outcomes.
Most previous epidemiologic studies of car-
diovascular risk, including the landmark Multi-
national Monitoring of Trends and Determinants 
in Cardiovascular Disease (MONICA) study,16 were 
conducted largely in wealthier countries (mainly 
Europe; see Fig. S2 in the Supplementary Appen-
dix), although the MONICA study and some 
other studies have included a few countries, such 
as China, that are at lower economic levels.17 The 
challenges of conducting a study that includes 
countries across a wide range of socioeconomic 
circumstances are considerable. However, such 
studies may provide important information that 
Figure 3. Annualized Case Fatality Rates after Specific Cardiovascular Events.
The case fatality rates, which are shown according to the income status of the 17 countries in the study, were adjusted for age and sex.
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cannot be obtained from analyses of single coun-
tries, especially if those analyses are confined to 
wealthy regions.
Our study has several limitations. First, it was 
not considered to be feasible to use strict pro-
portionate sampling in each country; therefore, 
caution is needed in interpreting our data as 
being representative of each country. However, 
the countries included are not atypical with re-
spect to the range of economic levels (Fig. S1 in 
the Supplementary Appendix); in addition, the 
risk-factor levels in each country in the PURE 
study parallel those in previous studies, the 
populations that were included in our study were 
similar to those that were eligible for inclusion, 
and the rates of death in each household in the 
2 years before inclusion in the study correlated 
closely with national rates of death and with 
those observed during follow-up (Fig. S3 and S4 
in the Supplementary Appendix).
Second, we were able to follow only 92.8% of 
our participants (97.5% of those in high-income 
countries, 94.4% of those in middle-income coun-
tries, and 85.9% of those in low-income coun-
tries). Follow-up rates were high in the rural ar-
eas of all countries and in the urban areas of 
high- and middle-income countries but were lower 
in the urban areas of low-income countries 
(76.8%). The rates in urban areas of low-income 
countries may have been lower because some 
housing areas were demolished or communities 
dispersed owing to social and economic unrest. 
Given the small proportion of participants for 
whom follow-up data were not available, adjust-
ment for the differences observed in INTERHEART 
risk scores and educational level between par-
ticipants with and those without follow-up data 
did not materially alter our conclusions.
Third, the detection of cardiovascular events 
(though not of death) may have been hampered 
by differences in access to hospital and diagnos-
tic facilities between lower-income countries 
and higher-income countries. However, if event 
detection were limited to a substantial extent 
because of reduced access in lower-income coun-
tries, it would imply that the rates of cardiovas-
cular events are actually even higher in those 
countries.
In conclusion, our large study of cardiac risk 
factors and cardiovascular events among adults 
in urban and rural communities in low-, middle-, 
and high-income countries on five continents 
showed that the incidence of major cardiovascu-
lar disease was highest in low-income countries, 
despite the fact that these countries had the low-
est risk-factor burden. Case fatality rates were 
also highest in the low-income countries. Rural 
communities had a lower risk-factor burden than 
urban communities but higher cardiovascular-
event rates and case fatality rates.
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